We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
Julie Anne Smith is president and chief executive officer and member of the board of directors. Prior to joining E-Scape, Ms. Smith was president and chief executive officer of Nuredis, a biotechnology company focused on neurodegenerative diseases caused by long nucleotide repeats such as Huntington's disease. She previously served as president and CEO of Raptor Pharmaceuticals, which developed and commercialized therapies for the orphan disease nephropathic cystinosis and chronic pulmonary infections in cystic fibrosis before its acquisition by Horizon Pharmaceuticals. Ms. Smith also served as chief commercial officer of Enobia Pharmaceuticals until it was acquired by Alexion in 2012.
Earlier in her career, she held roles at Jazz Pharmaceuticals, Genzyme, Novazyme and Bristol-Myers Squibb. Ms. Smith serves as a director on the boards of Exelixis, Inc. (EXEL) and Audentes Therapeutics (BOLD). Ms. Smith obtained her Bachelor of Science in biology from Cornell University.
This speaker's sessions: